Publication – Huntington's

Alexandrov V, Brunner D, Menalled LB, Kudwa A, Watson-Johnson J, Mazzella M, Russel I, Ruiz MC, Torello J, Sabath E, Sanchez A, Gomez M, Filipov I, Cox K, Kwan M, Ghavami A, Ramboz S, Lager B2, Wheeler VC, Aaronson J, Rosinski J, Gusella JF, MacDonald ME, Howland D, Kwak S.
Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice. 2016 doi:10.1038/nbt.3587

Menalled L & Brunner D.Animal Models of Huntington’s Disease for Translation to the Clinic: Best Practices. Movement Disorders 29(11): 1375-90 2014, 29, 1375-90.

Farrar AM, Murphy CA, Paterson NE, Oakeshott S, He D, Alosio W, McConnell K, Menalled LB, Ramboz S, Park LC, Howland D, Brunner D. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease. . 2014,  3, 145-58.

Menalled L, Kudwa A, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I and Howland DGenetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. PLoS One 2014, 9, e99520.

Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi SJ, Caricasole A, Landwehrmeyer B, Menalled L, Murphy C, Ramboz S, Luthi CR, Westerberg G, Marsh JL.A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. . 2014,  23, 2995-3007.

Moreno H, Lewandowski N, Bordelon Y, Brickman A, Angulo S, Khan U, Muraskin J, Griffith E, Wasserman P, Menalled L, Vonsattel J.P, Marder K, Small S.ARegional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease. Neurobiol Dis 2013, 52, 84-93.

Kudwa A, Menalled L, Oakeshott S, Murphy C, Mushlin R, Fitzpatrick J, Miller SF, McConnell K, Port R, Torello J, Howland D, Ramboz S, Brunner D. Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington's Disease Accounts for Some but Not All of the Observed HD-like Motor Deficits. PLoS Curr 2013,  5

Balci F, Oakeshott S, Shamy JS, El-Khodor BF, Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwa S, Brunner DHigh-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's Disease. PLoS Curr 2013, 5

Menalled L, El-Khodor BF, Hornberger M, Park L, Howland D, Brunner, D.Effect of the rd1 mutation on motor performance in R6/2 and wild type mice. PLoS Curr . 2012, RRN1303

Gafni J, Papanikolaou T, DeGiacomo F, Holcomb J, Chen S, Menalled L, Kudwa A, Fitzpatrick J, Miller S, Ramboz S, Tuunanen P, Lehtimaki K, William YX, Kwak S, Park L, Howland D, Park H, Ellerby L.Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci . 2012, 32, 7454-65

Menalled, L, Patry M, Ragland N, Lowden PA, Goodman J, Minnich J, Zahasky B, Park L, Leeds J, Howland D, Signer E, Tobin AJ, Brunner D.Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One 2010, e49838.

Cepeda-Prado E, Popp S, Khan U, Stefanov D, Rodrguez J, Menalled L, Dow-Edwards D, Small S, Moreno H.R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci. 2012,  32, 6456-67

Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D.Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease. PLoS Curr 2011, 3, RRN1225.

Menalled L, Patry M, Ragland N, Lowden PA, Goodman J, Minnich J, Zahasky B, Park L, Leeds J, Howland D, Signer E, Tobin AJ, Brunner D.Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010, 5, e9793.

Balci F, Day M, Rooney A, Brunner D. Disrupted temporal control in the R6/2 mouse model of Huntington's disease. Behav Neurosci 2009,  123, 1353-8

Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D.Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009,  35, 319-36.

Menalled L.Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2, 465-70.


  • PsychoGenics
  • 765 Old Saw Mill River Road, Tarrytown, NY 10591
  • tel: (914) 406-8019
  • fax: (914) 593-0645